4.7 Article

Fibrin activates GPVI in human and mouse platelets

期刊

BLOOD
卷 126, 期 13, 页码 1601-1608

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2015-04-641654

关键词

-

资金

  1. Wellcome Trust [073107, 088410]
  2. British Heart Foundation [PG/07/116, PG/05/134]
  3. Najran University [DLAB ROEH16283]
  4. Emmy Noether grant from the Deutsche Forschungsgemeinschaft [BE5084/3-1]
  5. British Heart Foundation [RG/13/18/30563] Funding Source: researchfish

向作者/读者索取更多资源

The glycoprotein VI (GPVI)-Fc receptor gamma (FcR gamma) chain is the major platelet signaling receptor for collagen. Paradoxically, in a FeCl3 injury model, occlusion, but not initiation of thrombus formation, is delayed in GPVI-deficient and GPVI-depleted mice. In this study, we demonstrate that GPVI is a receptor for fibrin and speculate that this contributes to development of an occlusive thrombus. We observed a marked increase in tyrosine phosphorylation, including the FcR gamma chain and Syk, in human and mouse platelets induced by thrombin in the presence of fibrinogen and the alpha IIb beta 3 blocker eptifibatide. This was not seen in platelets stimulated by a protease activated receptor (PAR)-4 peptide, which is unable to generate fibrin from fibrinogen. The pattern of tyrosine phosphorylation was similar to that induced by activation of GPVI. Consistent with this, thrombin did not induce tyrosine phosphorylation of Syk and the FcR gamma chain in GPVI-deficient mouse platelets. Mouse platelets underwent full spreading on fibrin but not fibrinogen, which was blocked in the presence of a Src kinase inhibitor or in the absence of GPVI. Spreading on fibrin was associated with phosphatidylserine exposure (procoagulant activity), and this too was blocked in GPVI-deficient platelets. The ectodomain of GPVI was shown to bind to immobilized monomeric and polymerized fibrin. A marked increase in embolization was seen following FeCl3 injury in GPVI-deficient mice, likely contributing to the delay in occlusion in this model. These results demonstrate that GPVI is a receptor for fibrin and provide evidence that this interaction contributes to thrombus growth and stability.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs

Maan H. Harbi, Christopher W. Smith, Fawaz O. Alenazy, Phillip L. R. Nicolson, Alok Tiwari, Steve P. Watson, Mark R. Thomas

Summary: The study investigates the effect of Syk inhibitor fostamatinib as an antiplatelet drug, showing that it mildly inhibits platelet responses induced by atherosclerotic plaque and that this effect is amplified by aspirin and ticagrelor.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Hematology

Oculocerebrorenal syndrome of Lowe protein controls cytoskeletal reorganisation during human platelet spreading

Ana Bura, Maria Antonietta de Matteis, Markus Bender, Maurice Swinkels, Jurjen Versluis, A. J. Gerard Jansen, Antonija Jurak Begonja

Summary: Lowe syndrome is a rare disorder that affects the brain, eyes, and kidneys. It is caused by mutations in the OCRL protein. Some patients with Lowe syndrome have bleeding disorders and impaired platelet function. Experiments show that OCRL inhibition affects cytoskeletal rearrangement in platelet activation, which may explain the mild bleeding problems in patients with Lowe syndrome.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Hematology

Treatment of congenital thrombocytopenia and decreased collagen reactivity in G6b-B-deficient mice

Alexandra Mazharian, Blandine Maitre, Alicia Bornert, Desline Hennequin, Marc Lourenco-Rodrigues, Mitchell J. Geer, Christopher W. Smith, Silke Heising, Michaela Walter, Florian Montel, Lucy S. K. Walker, Henri de la Salle, Steve P. Watson, Christian Gachet, Yotis A. Senis

Summary: Mice lacking the G6b-B receptor exhibit a range of platelet abnormalities, including macrothrombocytopenia and reduced collagen receptor expression. Treatment with romiplostim, a thrombopoietin mimetic, showed promising results in rescuing platelet counts and function in G6b KO mice. However, inhibitors targeting Syk and Src kinases had limited effects on platelet abnormalities. These findings suggest that romiplostim may be a potential therapeutic option for patients lacking functional G6b-B.

BLOOD ADVANCES (2023)

Article Hematology

Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibition

Philippe Billiald, Alexandre Slater, Martin Welin, Joanne C. Clark, Stephane Loyau, Martine Pugniere, Isabella G. Jiacomini, Nadia Rose, Kristell Lebozec, Elie Toledano, Deborah Francois, Steve P. Watson, Martine Jandrot-Perrus

Summary: This study shows that glenzocimab, a humanized antibody fragment, blocks the binding of GPVI to vascular collagen and fibrin through steric hindrance and structural change. This finding is significant for the development of new antiplatelet molecules with a low bleeding risk.

BLOOD ADVANCES (2023)

Article Cell Biology

Rapid isolation of mature murine primary megakaryocytes by size exclusion via filtration

Markus Spindler, Kristina Mott, Harald Schulze, Markus Bender

Summary: We demonstrate a simple and rapid method to enrich mature megakaryocytes (MKs) from murine adult bone marrow by size exclusion. Reanalysis of the isolated MKs confirmed the expression of MK and platelet-specific surface receptors, as well as a clear enrichment of MK-specific proteins/transcripts. This protocol serves as a compatible addition to established isolation methods.

PLATELETS (2023)

Article Hematology

Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thrombosis

Asim Cengiz Akbulut, Ryanne A. Arisz, Constance C. F. M. J. Baaten, Gaukhar Baidildinova, Aarazo Barakzie, Rupert Bauersachs, Jur Ten Berg, Wout W. A. van den Broek, H. C. de Boer, Amandine Bonifay, Vanessa Broker, Richard J. Buka, Hugo ten Cate, Arina J. ten Cate-Hoek, S. Cointe, Ciro De Luca, Ilaria De Simone, Rocio Vacik Diaz, Francoise Dignat-George, Kathleen Freson, Giulia Gazzaniga, Eric C. M. van Gorp, Anxhela Habibi, Yvonne M. C. Henskens, Aaron F. J. Iding, Abdullah Khan, Gijsje H. Koenderink, Akhil Konkoth, Romaric Lacroix, Trisha Lahiri, Wilbur Lam, Rachel E. Lamerton, Roberto Lorusso, Qi Luo, Coen Maas, Owen J. T. McCarty, Paola E. J. van der Meijden, Joost C. M. Meijers, Adarsh K. Mohapatra, Neta Nevo, Alejandro Pallares Robles, Philippe Poncelet, Christoph Reinhardt, Wolfram Ruf, Ronald Saraswat, Claudia Schonichen, Roger Schutgens, Paolo Simioni, Stefano Spada, Henri M. H. Spronk, Karlygash Tazhibayeva, Jecko Thachil, Rocio Vacik Diaz, L. Vallier, Alicia Veninga, Peter Verhamme, Chantal Visser, Steve P. Watson, Philip Wenzel, Ruth A. L. Willems, Anne Willers, Pengyu Zhang, Konstantinos Zifkos, Anton Jan van Zonneveld

Summary: The Fourth Maastricht Consensus Conference on Thrombosis covered a wide range of topics, including the role of coagulation proteins in cardiovascular disease, novel mechanisms of thrombosis, strategies to limit bleeding risks, hemostasis in extracorporeal systems, and clinical dilemmas in thrombosis and antithrombotic management. The conference also revisited the coagulopathy associated with COVID-19.

THROMBOSIS AND HAEMOSTASIS (2023)

Letter Hematology

Antibody-mediated depletion of human CLEC-2 in a novel humanized mouse model

Helena C. Brown, Sarah Beck, Stefano Navarro, Ying Di, Eva M. Soriano Jerez, Jana Kaczmarzyk, Steven G. Thomas, Valbona Mirakaj, Steve P. Watson, Bernhard Nieswandt, David Stegner

BLOOD ADVANCES (2023)

Article Biology

Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists

Joanne C. Clark, Eleyna M. Martin, Luis A. Moran, Ying Di, Xueqing Wang, Malou Zuidscherwoude, Helena C. Brown, Deirdre M. Kavanagh, Johan Hummert, Johannes A. Eble, Bernhard Nieswandt, David Stegner, Alice Y. Pollitt, Dirk-Peter Herten, Michael G. Tomlinson, Angel Garcia, Steve P. Watson

Summary: Fluorescence correlation spectroscopy was used to investigate the clustering of CLEC-2 induced by crosslinked nanobody ligands. The results showed that the valency of the ligands and the expression levels of CLEC-2 were important factors in determining the activation of CLEC-2. Divalent ligands were found to be partial agonists while tetravalent ligands stimulated platelet aggregation.

COMMUNICATIONS BIOLOGY (2023)

Article Hematology

Antagonistic Roles of Human Platelet Integrin aIIb beta 3 and Chemokines in Regulating Neutrophil Activation and Fate on Arterial Thrombi Under Flow

Claudia Schoenichen, Samantha J. Montague, Sanne L. N. Brouns, James J. Burston, Judith M. E. M. Cosemans, Kerstin Jurk, Beate E. Kehrel, Rory R. Koenen, Fionnuala Ni Ainle, Valerie B. O'Donnell, Oliver Soehnlein, Steve P. Watson, Marijke J. E. Kuijpers, Johan W. M. Heemskerk, Magdolna Nagy

Summary: This study reveals the key interaction mechanisms between platelets and neutrophils in arterial thrombus formation. Activated platelet integrin αIIbβ3 plays a role in preventing leukocyte adhesion, while platelet-released substances promote neutrophil activation. These findings provide insights for potential pharmacological intervention.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2023)

Editorial Material Pharmacology & Pharmacy

Validation of agent-based models of surface receptor oligomerisation

Joanne C. Clark, Steve P. Watson, Dylan M. Owen

Summary: This article discusses how a combination of agent-based modelling, advanced microscopy, and structural studies can provide new insights into the regulation of clustering, including spatial considerations, and reveal novel targets for therapeutic intervention.

TRENDS IN PHARMACOLOGICAL SCIENCES (2023)

Article Hematology

Characterizing the binding of glycoprotein VI with nanobody 35 reveals a novel monomeric structure of glycoprotein VI where the conformation of D1+D2 is independent of dimerization

Foteini-Nafsika Damaskinaki, Natalie J. Jooss, Eleyna M. Martin, Joanne C. Clark, Mark R. Thomas, Natalie S. Poulter, Jonas Emsley, Barrie Kellam, Steve P. Watson, Alexandre Slater

Summary: This study investigates the binding sites of three high-affinity nanobodies, Nb2, Nb21, and Nb35, on the platelet-signaling receptor GPVI. The researchers found that all three nanobodies can bind to the D1 domain of GPVI and inhibit collagen-induced GPVI signaling. They also identified common target residues, Arg46, Tyr47, and Ala57, on GPVI for these nanobodies. Additionally, the study negates the idea that GPVI dimerization induces a conformational change required for ligand binding.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Article Hematology

Fibrin-glycoprotein VI interaction increases platelet procoagulant activity and impacts clot structure

Julia S. Gauer, Cedric Duval, Rui-Gang Xu, Fraser L. Macrae, Helen R. McPherson, Christian Tiede, Darren Tomlinson, Steve P. Watson, Robert A. S. Ariens

Summary: The interaction between GPVI and fibrin significantly affects the formation of procoagulant platelets and the structure of blood clots. Inhibition of GPVI signaling increases clot porosity and impairs clot contractibility to varying degrees.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Article Hematology

Heparin and heparin proteoglycan-mimetics activate platelets via PEAR1 and PI3Kβ

Caroline Kardeby, Alice Evans, Joana Campos, Afraa Moosa Al-Wahaibi, Christopher W. Smith, Alexandre Slater, Eleyna M. Martin, Sonia Severin, Alexander Brill, Gunnar Pejler, Yi Sun, Steve P. Watson

Summary: English Summary: The study identified PEAR1 as a receptor for heparin and HPGM, and PI3K(3 as a key signaling molecule downstream of PEAR1 in platelets. These findings may provide important insights into the role of PEAR1 in cardiovascular disease.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Article Hematology

Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy

Fawaz O. Alenazy, Maan H. Harbi, Dean P. Kavanagh, Joshua Price, Paul Brady, Oscar Hargreaves, Paul Harrison, Alexandre Slater, Alok Tiwari, Phillip L. R. Nicolson, Derek L. Connolly, Paulus Kirchhof, Neena Kalia, Martine Jandrot-Perrus, Pierre H. Mangin, Steve P. Watson, Mark R. Thomas

Summary: This study investigated the additional antithrombotic effects of combining glenzocimab, a GPVI inhibitor, with aspirin and ticagrelor. The results showed that glenzocimab enhanced platelet inhibition and reduced atherosclerotic plaque-induced platelet aggregation, adhesion, and activation. Compared to a GPIIb/IIIa inhibitor, glenzocimab exhibited similar antithrombotic effects but with less inhibition of general hemostasis.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

暂无数据